Abstract:Objective: To assess the effects of pharmacological therapies for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Patients and methods: We performed a comprehensive search using multiple databases, trial registries, grey literature and conference proceedings with no restrictions on the language of publication or publication status. The date of the latest search of all databases was July 2019. We included randomised controlled trials. Inclusion criteria were men with a diagnosis of CP/CPPS. We included all available pharmacological interventions. Two review authors independently classified studies and abstracted data from the included studies, performed statistical analyses and rated quality of evidence according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methods. The primary outcomes were prostatitis symptoms and adverse events. The secondary outcomes were sexual dysfunction, urinary symptoms, quality of life, anxiety and depression. Results: We included 99 unique studies in 9119 men with CP/CPPS, with assessments of 16 types of pharmacological interventions. Most of our comparisons included short-term follow-up information. The median age of the participants was 38 years. Most studies did not specify their funding sources; 21 studies reported funding from pharmaceutical companies. We found low- to very low-quality evidence that α-blockers may reduce prostatitis symptoms based on a reduction in National Institutes of Health - Chronic Prostatitis Symptom Index (NIH-CPSI) scores of >2 (but <8) with an increased incidence of minor adverse events such as dizziness and hypotension. Moderate- to low-quality evidence indicates that 5α-reductase inhibitors, antibiotics, anti-inflammatories, and phytotherapy probably cause a small decrease in prostatitis symptoms and may not be associated with a greater incidence of adverse events. Intraprostatic botulinum toxin A (BTA) injection may cause a large reduction in prostatitis symptoms with procedure-related adverse events (haematuria), but pelvic floor muscle BTA injection may not have the same effects (low-quality evidence). Allopurinol may also be ineffective for reducing prostatitis symptoms (low-quality evidence). We assessed a wide range of interventions involving traditional Chinese medicine; low-quality evidence showed they may reduce prostatitis symptoms without an increased incidence in adverse events. Moderate- to high-quality evidence indicates that the following interventions may be ineffective for the reduction of prostatitis symptoms: anticholinergics, Escherichia coli lysate (OM-89), pentosan, and pregabalin. Low- to very low-quality evidence indicates that antidepressants and tanezumab may be ineffective for the reduction of prostatitis symptoms. Low-quality evidence indicates that mepartricin and phosphodiesterase inhibitors may reduce prostatitis symptoms, without an increased incidence in adverse events. Conclusions: Based on the findings of low- to very low-quality evidence, this review found that some pharmacological interventions such as α-blockers may reduce prostatitis symptoms with an increased incidence of minor adverse events such as dizziness and hypotension. Other interventions may cause a reduction in prostatitis symptoms without an increased incidence of adverse events while others were found to be ineffective.

Qian Lie an Suppository (prostant) for Chronic Prostatitis

Qian Lie An Suppository (Prostant) For Chronic Prostatitis A Systematic Review And Meta-Analysis Of Randomized Controlled Trials

Prostatic Calculi Influence the Antimicrobial Efficacy in Men with Chronic Bacterial Prostatitis

Fluoxetine Ameliorates Symptoms of Refractory Chronic Prostatitis/chronic Pelvic Pain Syndrome.

[A Multi-Center Clinical Trial of Qianlieantong Tablets for Chronic Prostatitis].

[A Clinical Study of Prostat Combined with an Antibiotic for Chronic Nonbacterial Prostatitis].

[Clinical Observation on Therapeutic Effect of Suspended Moxibustion on Temperature-Sensitive Acupoints Plus Medication for Chronic Prostatitis].

The Efficacy and Safety of ProstantTM in the Treatment of Chronic Prostatitis:A Multi Center, Randomized, Double Blinded, Placebo Controlled Trial

The Efficacy and Safety of ProstantTM in the Treatment of Chronic Prostatitis: a Multi-Center,randomized,double-blind,placebo-controlled Clinical Trial

[Transperineal Ultrasonic Therapy for Chronic Prostatitis].

New Therapy with XLQ® to Suppress Chronic Prostatitis Through Its Anti‐inflammatory and Antioxidative Activities

Treatment of chronic prostatitis in Chinese men.

Clinical Observation of Azithromycin Combined with Doxazosin and Qianlieanshuan in the Treatment of NIH Ⅲ Prostatitis

A Clinical Survey of Combined Use of Different Drugs in the Treatment of Chronic Prostatitis(report of 153 Cases)

Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome: a Cochrane systematic review

Clinical Research on Treating Chronic Prostatitis from Blood Stasis and Blood Turbid Aspect in Different Treatment Stages

Exploring the Efficacy of the Traditional Chinese Medicine Compound Formulas Qianlong Shutong Formula in the Treatment of Benign Prostatic Hyperplasia

The Clinical Effect and Mechanism of Prostant on Urinary Retention and Anal Pain

[Dongbai Tonglin Mixture for the treatment of chronic prostatitis]

[Effect and Mechanism of Alpha1-Adrenoceptor Blocker Combined with Antibiotics for Chronic Prostatitis].

Pharmacological Interventions for Bacterial Prostatitis